The Need for Novel Treatment Strategies for R/R Multiple Myeloma
Robert Rifkin, MD, FACP, a hematology oncologist at the Rocky Mountain Cancer Centers, discusses the need for novel treatment options in the relapsed or refractory multiple myeloma population.
Robert Rifkin, MD, FACP, a hematology oncologist at the Rocky Mountain Cancer Centers, discusses the need for novel treatment options in the relapsed or refractory (R/R) multiple myeloma population.
According to Rifkin, currently, multiple myeloma is not being cured despite the fact that the common frontline lenalidomide (Revlimid), Bortezomib (Velcade), and dexamethasone (RVD) tends to be very effective in getting patients to stem cell transplant. The problem is that patients often become relapsed or refractory after transplantation, meaning novel treatment approaches are warranted.
Rifkin said that this is the area where the need for new approaches such as an antibody drug conjugate or chimeric antigen receptor-T cell therapy are the most ideal. The need for new therapies is the highest in patients who relapsed after being treated with the RVD regimen.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
